Phase 4
N=888
Pharmacogenomic Evaluation of Antihypertensive Responses
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT00246519 ↗Enrolled (actual)
888
Serious AEs
0.5%
Results posted
Jul 2013
Primary outcome: Primary: Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). — -12.06; -13.33 mmHg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Hydrochlorothiazide (Drug); Atenolol (Drug)
- Age
- Pediatric, Adult, Older Adult · 17+ yrs
- Sex
- All
- Sponsor
- University of Florida
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). |
-12.06; -13.33 | — |
| SECONDARY Adverse Metabolic Responses |
— | — |
Summary
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that only 34% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, we may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
Eligibility Criteria
Inclusion Criteria
An average seated home diastolic blood pressure (DBP) > 85 mmHg and home systolic blood pressure (SBP) 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP 1.5 in men or 1.4 in women), primary renal disease, pregnancy or lactation, liver enzymes > 2.5 upper limits of normal, current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral contraceptives or estrogen.
Data sourced from ClinicalTrials.gov (NCT00246519). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.